Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Daiichi Sankyo's Tribenzor

The US Food and Drug Administration has approved Daiichi Sankyo's Tribenzor – a combination drug for high blood pressure

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo's Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) – a combination drug for high blood pressure.

The drug is not approved for initial use, but can be administered to patients suffering from hypertension whose condition is not controlled by a combination of any two of the specified antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers and diuretics.

Tribenzor works as a combination of medications to relax blood vessels so blood can flow more freely. Olmesartan medoxomil blocks angiotensin II receptors; amlodipine blocks calcium entering into the blood vessel walls; and hydrochlorothiazide reduces water volume in the blood.

Olmesartan is sold by Daiichi under the brandnames Benicar and Olmetec; amlodipine is sold by Pfizer as Norvasc; and hydrochlorothiazide is available both as a generic and as branded products sold by a range of manufacturers.

Around 56 per cent of patients currently in treatment for the condition do not reach existing recommendations in blood pressure levels, according to Daiichi Sankyo. More than two-thirds of patients with high blood pressure will be prescribed two or more antihypertensive medications to reach these outcomes.

"Generally speaking, it can be a struggle for some patients who need to take multi-pill regimens to take their medications as prescribed," said Dr Joseph L Izzo, chief of medicine, Erie County Medical Center, Buffalo, New York.

"Tribenzor is a three-in-one pill that offers a simple, convenient and consistently effective therapy for patients, and may be just what some patients need to help bring their blood pressure to goal," he continued.

27th July 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...